Does Surging Genomics Consumables Demand Reshape The Bull Case For Illumina’s Recurring Revenue Engine (ILMN)?

Recent industry reports have highlighted past and projected rapid expansion in the DNA diagnostics and genomics markets, driven by liquid biopsies, direct-to-consumer testing, and personalized ...

Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually

Illumina, Inc. (NASDAQ: ILMN) and MyOme, a leading genomics innovation and risk modeling company, today announced a collaboration and investment by Illumina into MyOme. The collaboration and investmen ...

Zacks.com featured highlights include Illumina, Commercial Metals and Newmont

Illumina, Commercial Metals and Newmont stand out as brokers boost ratings amid inflation concerns and shifting economic signals.
TipRanks on MSN

Illumina, MyOme announces collaboration, investment by Illumina into MyOme

Illumina (ILMN) and MyOme announced a collaboration and investment by Illumina into MyOme. The collaboration and investment will help advance ...
The Motley Fool

Better Gene Sequencing Stock: Illumina vs. Bionano Genomics

Most biopharma players need access to gene sequencing services. Illumina is facing a handful of headwinds, but it's still the market leader. Bionano Genomics is unproven but expanding quickly. So ...
The New York Times

Gene-Sequencing Company Illumina to Sell Cancer Test Developer

The move came two days after a court upheld the Federal Trade Commission’s challenge to the deal on antitrust grounds. By Nicole Sperling Illumina, the leading producer of gene-sequencing machines, ...
Nasdaq

Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions

Longstanding partners bring together end-to-end workflows and leading CRISPRPerturb-seq technologies setting a standard for single-cell studies and enabling a 5billion single-cell atlas ecosystem ...
Morningstar

Illumina Should Dominate in High-Throughput Sequencing

Illumina’s announced partnerships with IBM’s Watson and Philips help shore up the firm's data-analysis capabilities and clinical diagnostic marketing efforts, respectively, but the announcement of a ...
The New York Times

F.T.C. Orders Gene-Sequencing Company Illumina to Divest Acquisition

The move by the commission is seen as a test of regulators’ efforts to prevent big companies from buying small innovators. By Steve Lohr Steve Lohr first wrote about Illumina’s confrontation with the ...
News Medical

Illumina launches its first product enabling long- and short-read sequencing on one instrument

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first product based on its novel Illumina Complete Long Read technology is now ...
Morningstar

Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions

"Illumina has set the standard in whole genome sequencing, and now, with Broad's deep experience and long history of translating complex molecular biology assays into high-throughput, high quality ...